

KURZPROTOKOLL
Target-NASH

Öffentlicher Titel	Beobachtungsstudie bei nicht-alkoholischer Fettlebererkrankung (NAFLD) und nicht-alkoholischer Steatohepatitis (NASH)
Wissenschaftl. Titel	A 5-year Longitudinal Observational Study of Patients with Nonalcoholic Fatty Liver (NAFL) or Nonalcoholic Steatohepatitis (NASH)
Kurztitel	Target-NASH
Studienart	multizentrisch, prospektiv, offen/unverblindet, einarmig, Register
Studienphase	nicht zutreffend
Erkrankung	Verdauung: Lebererkrankungen: Nicht-alkoholische Steatohepatitis (NASH) Verdauung: Lebererkrankungen: Nichtalkoholische Fettlebererkrankung (NAFLD) Kinder: Lebererkrankungen
Einschlusskriterien	- Adults and children (age 2 or older) being managed or treated for nonalcoholic fatty liver disease. Diagnosis is based on the clinical judgement of the care provider.
Ausschlusskriterien	- Inability to provide written informed assent/consent - Simultaneous enrollment in another registry, study, or clinical trial where NASH treatment outcomes are reported, except where approved or conducted as an adjunct project of TARGET-NASH. If a participant elects to enroll in an interventional clinical trial during their enrollment in TARGET-NASH, records submissions for the participant will be put 'on hold' for the trial duration. When participation in the trial is complete, records submissions for TARGET-NASH will resume.
Alter	2 Jahre und älter
Prüfzentren	Innere Medizin 1 (Geschlossen) Gastroenterologie / Hepatologie Theodor-Stern-Kai 7 60590 Frankfurt am Main Prof. Dr. med. Stefan Zeuzem Tel: 069 6301-87769 Fax: 069 6301-6580 stefan.zeuzem@unimedizin-ffm.de
Sponsor	Target PharmaSolutions
Registrierung in anderen Studienregistern	ClinicalTrials.gov NCT02815891 (primäres Register)